Laurus实验室为扩大生物制造和开发新产品提供了14.2M美元的投资。 Laurus Labs secures $14.2M investment to expand bio-manufacturing and develop new products.

一家印度制药公司Laurus Labs为其子公司Laurus Bio公司从风险资本公司八路风险投资公司和F-Prime Capital公司获得了120克朗(1 420万美元)的股权投资。 Laurus Labs, an Indian pharmaceutical company, has secured a ₹120 crore ($14.2 million) equity investment for its subsidiary Laurus Bio from venture capital firms Eight Roads Ventures and F-Prime Capital. 这些资金将用于扩大以发酵为基础的制造能力和开发新产品。 The funds will be used to expand fermentation-based manufacturing capabilities and develop new products. 投资后、劳鲁斯实验室、八条路风险投资公司和劳鲁斯生物促进公司将分别持有75%、14%和9%的股份。 Post-investment, Laurus Labs, Eight Roads Ventures, and Laurus Bio promoters will hold 75%, 14%, and 9% stakes, respectively.